New biomarker strategies to enable precision cardiovascular medicine

Area of Science:

• Cardiovascular Medicine
• Genomics
• Biomarker Discovery

Background:

• Precision medicine integrates genomic, personal, and environmental factors for tailored disease treatment and prevention.
• Cardiovascular diseases (CVD) have complex etiologies, with rare monogenic causes and increasing focus on polygenic risk and environmental influences.
• Emerging research explores novel pathways and therapeutic targets, including PCSK9 inhibitors for familial hypercholesterolemia and myosin ATPase inhibitors for hypertrophic cardiomyopathy.

Purpose of the Study:

• To review emerging biomarker strategies for precision cardiovascular medicine.
• To highlight how genomic and environmental factors inform CVD prevention and treatment.
• To showcase novel therapeutic targets identified through genetic and metabolomic insights.

Main Methods:

• Literature review of recent advancements in precision cardiovascular medicine.
• Analysis of biomarker strategies including genetic variants, polygenic risk scores, and metabolomic insights.
• Examination of case studies illustrating the application of precision medicine in CVD.

Main Results:

• Biomarker strategies, including genetic and metabolomic approaches, are crucial for identifying individuals at high risk for CVD.
• Rare genetic variants and extreme phenotypes have led to the discovery of novel therapeutic targets like PCSK9 inhibitors.
• Polygenic risk scores and metabolomic insights, such as gut microbiota-derived pathways, offer new avenues for CVD susceptibility modulation.

Conclusions:

• Operationalizing precision cardiovascular medicine requires robust knowledge systems and data infrastructure.
• Integrating genetic and environmental data is essential for effective CVD prevention and treatment.
• Advancements in biomarker discovery are paving the way for personalized cardiovascular care.